

Jan 20, 2025

Nobelpharma Co., Ltd.

**Approval of healthcare insurance reimbursement for HYFTOR 2mg/g gel
(sirolimus) in Scotland**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Managing Director & CEO: Mr. Jin Shiomura) announced that its British subsidiary Plusultra pharma UK Ltd. (Oxford, United Kingdom, Managing Director: Takahiro Yamasaki) product HYFTOR 2mg/g gel (sirolimus), was approved healthcare insurance reimbursement for HYFTOR on January 13th, 2025, by the Scottish Medicines Consortium (SMC). HYFTOR is approved as the indication for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older *.

We are determined to continue contributing to society by providing critical but neglected pharmaceuticals and medical devices.

*: The indications for which it has been approved in Japan is skin lesions associated with tuberous sclerosis complex.

[Contact for inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800